title: Effects of atorvastatin combined with trimetazidine on myocardial injury and inflammatory mediator in unstable angina patients during perioperative of percutaneous coronary intervention.
abstract: OBJECTIVE
  To investigate the effects of atorvastatin combined with trimetazidine on periprocedural myocardial injury and serum inflammatory mediators in unstable angina pectoris (UAP) patients following percutaneous coronary intervention (PCI) treatment.
  
  
  METHODS
  90 patients with UAP treated with conventional medications and PCI were recruited and were randomly divided into the control group and the experimental group. The control group had 42 patients were treated with atorvastatin alone, while the experimental group had 48 cases treated with atorvastatin combined with trimetazidine. All the patients were checked the preoperative 24h and postoperative 24h PCI concentrations of cardiac troponin I (cTnI), hypersensitive C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), serum interferon-γ (IFN-γ) and interlukin-10 (IL-10).
  
  
  RESULTS
  At the pre-PCI stage, every serum factors was no significant difference. 24 hours after the PCI intervention, the occurence of abnormal cTnI level in the experimental group was remarkable reduced than the control group. In the experimental group, the serum levels of TNF-α and IFN-γ significantly decreased (p < 0.05); while IL-10 was increased. In the control group, all the mediators were increased significantly except the hs-CRP (p < 0.05).
  
  
  CONCLUSIONS
  No unexpected symptom was found in patients with large dose atorvastatin combined with large dose trimetazidine. The administration of conventional medications together with the atorvastatin plus trimetazidine were able to reduce the prevalence of postoperative myocardial injury.
authors.affiliation: Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, China. zhangjinyun2852@163.com.
authors.forename: J
authors.initials: J
authors.lastname: Hao
authors.forename: H
authors.initials: H
authors.lastname: Du
authors.forename: W-W
authors.initials: WW
authors.lastname: Li
authors.forename: Z-F
authors.initials: ZF
authors.lastname: Zhao
authors.forename: F
authors.initials: F
authors.lastname: Liu
authors.forename: J-C
authors.initials: JC
authors.lastname: Lu
authors.forename: X-C
authors.initials: XC
authors.lastname: Yang
authors.forename: W
authors.initials: W
authors.lastname: Cui
mesh_terms: D000368:Aged; D000789:Angina, Unstable / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology / Q000601:surgery*; D000069059:Atorvastatin / Q000008:administration & dosage* / Q000009:adverse effects; D002097:C-Reactive Protein / Q000378:metabolism; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D005260:Female; D006335:Heart Injuries / Q000097:blood / Q000453:epidemiology*; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood*; D007371:Interferon-gamma / Q000097:blood; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000379:methods*; D059035:Perioperative Period; D011183:Postoperative Complications / Q000097:blood / Q000453:epidemiology; D014292:Trimetazidine / Q000008:administration & dosage* / Q000009:adverse effects; D019210:Troponin I / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D018836:Inflammation Mediators; D019210:Troponin I; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; D002097:C-Reactive Protein; D000069059:Atorvastatin; D014292:Trimetazidine